Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Zuping, Xia"'
Autor:
Andrew S. Kraft, Charles D. Smith, Michael Lilly, Zuping Xia, Jian Ma, Fengxue Zhang, Sandeep Mahajan, Marina Zemskova, Zanna Beharry
Supplementary Data from Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21534fae2470cd669f218624a2789999
https://doi.org/10.1158/1535-7163.22485074.v1
https://doi.org/10.1158/1535-7163.22485074.v1
Autor:
Andrew S. Kraft, Charles D. Smith, Michael Lilly, Zuping Xia, Jian Ma, Fengxue Zhang, Sandeep Mahajan, Marina Zemskova, Zanna Beharry
The Pim protein kinases play important roles in cancer development and progression, including prostate tumors and hematologic malignancies. To investigate the potential role of these enzymes as anticancer drug targets, we have synthesized novel benzy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea0c65864b7f4450d6f54f83d336ffb
https://doi.org/10.1158/1535-7163.c.6531761.v1
https://doi.org/10.1158/1535-7163.c.6531761.v1
Publikováno v:
Drug Metabolism and Disposition. 49:1047-1055
Exemestane (EXE) is a hormonal therapy used to treat estrogen receptor positive (ER+) breast cancer by inhibiting the final step of estrogen biosynthesis catalyzed by the enzyme aromatase. Cysteine conjugates of EXE and its active metabolite 17β-dih
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f73037df3d8f71eb1e721e2b0c1bcb3c
https://doi.org/10.1124/dmd.121.000635
https://doi.org/10.1124/dmd.121.000635
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 8, Pp 1873-1884 (2007)
Many important signaling proteins require the posttranslational addition of fatty acid chains for their proper subcellular localization and function. One such modification is the addition of palmitoyl moieties by enzymes known as palmitoyl acyltransf
Externí odkaz:
https://doaj.org/article/5616007ccd5c49a1946b3022b20c9355
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 49(12)
Exemestane (EXE) is a hormonal therapy used to treat estrogen receptor-positive breast cancer by inhibiting the final step of estrogen biosynthesis catalyzed by the enzyme aromatase. Cysteine conjugates of EXE and its active metabolite 17β-dihydro-E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74c82e3f38fde33f7d32884d0a9551a9
https://pubmed.ncbi.nlm.nih.gov/34593616
https://pubmed.ncbi.nlm.nih.gov/34593616
Publikováno v:
Drug Metabolism and Disposition
Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of estrogen receptor–positive breast cancer. Although the known major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::109a8aadc471419481b5851bbf90d379
https://doi.org/10.1124/dmd.118.081166
https://doi.org/10.1124/dmd.118.081166
Autor:
Gang Chen, Zuping Xia, Pramod Kumar Srivastava, Christy J. W. Watson, Travis T. Denton, Alec Wynd, Philip Lazarus
Publikováno v:
Journal of Medicinal Chemistry. 61:7065-7086
Cigarette smoking causes nearly one in every five deaths in the United States. The development of a specific inhibitor of cytochrome P450 2A6 (CYP2A6), the major nicotine-metabolizing enzyme in humans, which could be prescribed for the cessation of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb49a8edea1ca4174ca779181f81619
https://doi.org/10.1021/acs.jmedchem.8b00084
https://doi.org/10.1021/acs.jmedchem.8b00084
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a817eeeb7d6c4db88fa558378dbb3784
https://doi.org/10.1096/fasebj.2019.33.1_supplement.508.7
https://doi.org/10.1096/fasebj.2019.33.1_supplement.508.7
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a926aead8544367f6829aa328225ecfd
https://doi.org/10.1096/fasebj.2019.33.1_supplement.508.8
https://doi.org/10.1096/fasebj.2019.33.1_supplement.508.8
Publikováno v:
Pharmacogenetics and Genomics. 26:370-380
Objective Exemestane (EXE) is a potent third-generation aromatase inhibitor used as endocrine therapy in breast cancer treatment and prevention. Characterization of its metabolic pathway is incomplete, with ambiguity existing in the identity of enzym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99aa73da0b2290ded97014bb7ac6ce40
https://doi.org/10.1097/fpc.0000000000000226
https://doi.org/10.1097/fpc.0000000000000226